What is the level of liabilities of IGC Pharma this year?
IGC Pharma has a debt balance of 2.58 M USD this year.
IGC Pharma Liabilities 2024
IGC Pharma Liabilities
2.58 M USD
Ticker
IGC
ISIN
US45408X3089
WKN
A1T87A
In 2024, IGC Pharma's total liabilities amounted to 2.58 M USD, a -12.21% difference from the 2.94 M USD total liabilities in the previous year.
IGC Pharma Aktienanalyse
What does IGC Pharma do?
India Globalization Capital Inc. (IGC) is a Maryland-based company that focuses on the development, marketing, and sale of natural supplements, novel cannabis formulations, food and beverages, and the manufacturing of medical devices. IGC was established in 2005 and initially operated as a construction company in India. However, over the years, the company has evolved into a diversified company based in Maryland due to its innovative products and services. One of IGC's most well-known divisions is IGC Pharma, which focuses on cannabis-based medical formulations and medical devices. IGC holds patent applications for certain cannabis-based products and was one of the first companies to explore the use of cannabis as a potential treatment for Alzheimer's patients. In collaboration with the Institute for Medicine and the Origins of Infancy at the University of Maryland, IGC developed a novel THC-based medication for the treatment of spasms, pain, and other symptoms in multiple sclerosis patients. IGC has also developed the "Hyalolex" product, which is made from specific cannabinoids such as CBD. This preparation is available in Germany under the trade name "Cannabidiol Hexal." Hyalolex is available as a dietary supplement and has been proven effective in improving memory performance, attention, and cognitive abilities in Alzheimer's patients. IGC also operates the IGC Nutraceuticals division, which focuses on the manufacturing and marketing of high-quality natural products. These include vitamins, minerals, dietary supplements, and natural herbal supplements that promote physical and mental well-being and support healthy bodily processes. Some of IGC Nutraceuticals' products include Saffron for Depression Relief, the calcium and magnesium formulation, and Bharat Diagnostics. IGC will continue to invest in various fields, including cannabis-based pain relief, dementia treatments, electrochemical energy storage, and the manufacturing of devices that utilize natural resources such as coal and ore. Overall, IGC has become a diversified company that focuses on a variety of industries. IGC has been a pioneer in the cannabis industry and has gained a good reputation through innovative formulations and patents. By expanding into new industries and investing in new technologies, IGC will continue to stay at the forefront of innovation and strengthen its position as one of the emerging development companies in today's economy. IGC Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing IGC Pharma's Liabilities
IGC Pharma's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating IGC Pharma's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing IGC Pharma's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
IGC Pharma's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in IGC Pharma’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about IGC Pharma stock
What were the liabilities of IGC Pharma compared to the previous year?
The liabilities of IGC Pharma have increased by -12.21% dropped compared to the previous year.
What are the consequences of high debt for investors of IGC Pharma?
High liabilities can pose a risk for investors of IGC Pharma, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in IGC Pharma?
Low liabilities mean that IGC Pharma has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of IGC Pharma affect the company?
An increase in liabilities of IGC Pharma can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of IGC Pharma affect the company?
A decrease in the liabilities of IGC Pharma can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of IGC Pharma?
Some factors that can influence the liabilities of IGC Pharma include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of IGC Pharma so important for investors?
The liabilities of IGC Pharma are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can IGC Pharma take to modify the liabilities?
To change its liabilities, IGC Pharma can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does IGC Pharma pay?
Over the past 12 months, IGC Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, IGC Pharma is expected to pay a dividend of 0 USD.
What is the dividend yield of IGC Pharma?
The current dividend yield of IGC Pharma is .
When does IGC Pharma pay dividends?
IGC Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of IGC Pharma?
IGC Pharma paid dividends every year for the past 0 years.
What is the dividend of IGC Pharma?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is IGC Pharma located?
IGC Pharma is assigned to the 'Industry' sector.
Wann musste ich die Aktien von IGC Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of IGC Pharma from 11/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/29/2024.
When did IGC Pharma pay the last dividend?
The last dividend was paid out on 11/29/2024.
What was the dividend of IGC Pharma in the year 2023?
In the year 2023, IGC Pharma distributed 0 USD as dividends.
In which currency does IGC Pharma pay out the dividend?
The dividends of IGC Pharma are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The IGC Pharma stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von IGC Pharma
Our stock analysis for IGC Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of IGC Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
